St. Jude Children’s Research Hospital has the first and only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. This designation reflects leading excellence in laboratory, clinical and survivorship research, as well as leadership in education and community outreach.
In partnership with SIOP, St. Jude is offering health care providers a site to collaborate, connect and find the latest information on COVID-19 as it relates to childhood cancer.
St. Jude Cloud is a data-sharing resource for the global research community. Explore one of the world's largest repositories of next-generation sequencing data and analysis tools for pediatric cancer.
St. Jude has been a global leader in influenza research for nearly 50 years. Working with investigators around the world, our experts conduct disease surveillance, increase understanding of influenza outbreaks and disease, and improve treatments and vaccines.
Transcription therapy is an emerging field used to study the causes of abnormal gene expression in pediatric leukemias, gliomas, brain cancers, and neurological and immune disorders. Find out how researchers at St. Jude are using transcription therapy to create more effective targeted treatments for our patients.
Gene therapy treats genetic diseases by giving patients a healthy version of a defective gene. St. Jude is developing innovative gene therapy approaches for patients with blood diseases, immune disorders and other conditions.
St. Jude has been committed to treating and curing sickle cell disease since its opening in 1962. From birth to adulthood, we help patients live with sickle cell disease, while we continue to research new cures and better long-term care.
Truly translational research is the cornerstone of St. Jude, where scientists and clinicians work together as a way of life. On-campus infrastructure helps us translate laboratory breakthroughs into clinical trials and innovative new treatments for patients.
The roots of pediatric cancer are hidden deep within a child’s DNA. The St. Jude-Washington University Pediatric Cancer Genome Project is the world’s most ambitious effort to discover the origins of childhood cancer and seek new cures.
Improved treatments for childhood cancer have helped swell the ranks of survivors to an estimated 420,000 individuals nationwide. St. Jude is pioneering the field of cancer survivorship with major research programs that follow thousands of survivors for decades after their treatment.
The Pediatric Translational Neuroscience Initiative (PTNI) leverages the scientific strength and expertise in experimental therapeutics of St. Jude to rise to the challenge of altering the landscape of pediatric neurological disease.